JOP20190164A1 - تركيبات وطرق لعلاج داء فاربر - Google Patents

تركيبات وطرق لعلاج داء فاربر

Info

Publication number
JOP20190164A1
JOP20190164A1 JOP/2019/0164A JOP20190164A JOP20190164A1 JO P20190164 A1 JOP20190164 A1 JO P20190164A1 JO P20190164 A JOP20190164 A JO P20190164A JO P20190164 A1 JOP20190164 A1 JO P20190164A1
Authority
JO
Jordan
Prior art keywords
compositions
methods
farber disease
treating farber
treating
Prior art date
Application number
JOP/2019/0164A
Other languages
English (en)
Inventor
Edward H Schuchman
Original Assignee
Icahn School Med Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School Med Mount Sinai filed Critical Icahn School Med Mount Sinai
Publication of JOP20190164A1 publication Critical patent/JOP20190164A1/ar
Application granted granted Critical
Publication of JOP20190164B1 publication Critical patent/JOP20190164B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01023—Ceramidase (3.5.1.23)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

غير متوفر
JOP/2019/0164A 2017-01-13 2018-01-12 تركيبات وطرق لعلاج داء فاربر JOP20190164B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762446166P 2017-01-13 2017-01-13
PCT/US2018/013509 WO2018132667A1 (en) 2017-01-13 2018-01-12 Compositions and methods for treating farber disease

Publications (2)

Publication Number Publication Date
JOP20190164A1 true JOP20190164A1 (ar) 2019-07-02
JOP20190164B1 JOP20190164B1 (ar) 2023-09-17

Family

ID=62839661

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0164A JOP20190164B1 (ar) 2017-01-13 2018-01-12 تركيبات وطرق لعلاج داء فاربر

Country Status (8)

Country Link
US (3) US20190343936A1 (ar)
EP (2) EP4295903A3 (ar)
JP (2) JP2020514305A (ar)
AU (1) AU2018207564A1 (ar)
CA (1) CA3049771A1 (ar)
JO (1) JOP20190164B1 (ar)
MX (1) MX2019008038A (ar)
WO (1) WO2018132667A1 (ar)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019009979A1 (en) * 2017-07-06 2019-01-10 The Medical College Of Wisconsin, Inc. NEW IN VITRO AND IN VIVO ENRICHMENT STRATEGY TARGETING CSH-DERIVED LYMPHOCYTES TRANSDUCED BY A VECTOR FOR DISEASE THERAPY
RU2020118032A (ru) * 2018-02-02 2022-03-02 Асераген, Инк. Способы лечения болезни фарбера
WO2020152532A1 (en) 2019-01-23 2020-07-30 Enzyvant Therapeutics Gmbh Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2854910T (lt) * 2012-06-01 2020-05-25 Icahn School Of Medicine At Mount Sinai Ceramido lygiai infekcijos gydymo ir prevencijos metu
PT2968479T (pt) 2013-03-14 2019-08-07 Icahn School Med Mount Sinai Composições terapêuticas de ceramidase ácida e métodos de fabrico e utilização
WO2019060837A1 (en) * 2017-09-25 2019-03-28 Enzyvant Farber Gmbh PROCESS FOR PRODUCING RECOMBINANT HUMAN ACID CERAMIDASE
RU2020118032A (ru) * 2018-02-02 2022-03-02 Асераген, Инк. Способы лечения болезни фарбера

Also Published As

Publication number Publication date
JP2023011938A (ja) 2023-01-24
AU2018207564A1 (en) 2019-08-08
EP4295903A2 (en) 2023-12-27
EP3568154B1 (en) 2023-07-12
US20190343936A1 (en) 2019-11-14
US20240075113A1 (en) 2024-03-07
JOP20190164B1 (ar) 2023-09-17
CA3049771A1 (en) 2018-07-19
EP3568154A1 (en) 2019-11-20
EP3568154A4 (en) 2020-11-18
US20220313800A1 (en) 2022-10-06
EP4295903A3 (en) 2024-03-27
MX2019008038A (es) 2020-02-05
WO2018132667A1 (en) 2018-07-19
JP2020514305A (ja) 2020-05-21

Similar Documents

Publication Publication Date Title
MX2021006235A (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
MX2019007021A (es) Anticuerpos il-11ra.
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
MX2019007020A (es) Anticuerpos il-11.
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
MX2022003891A (es) Anticuerpos anti-muc16 y sus usos.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
EA201890493A1 (ru) РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ
MD3209381T2 (ro) Compoziții care conțin tulpini bacteriene
MY191581A (en) Anti-pd-1 antibodies
GB2541571A (en) Pharmaceutical compositions
SG10201803042PA (en) Anti-tim-3 antibodies
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
SA518391831B1 (ar) تركيبات وطرق لخفض تعبير البروتين تاو
MX2019010492A (es) Kits y metodos para preparar composiciones de plaquetas con patogeno inactivado.
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
PH12017500602A1 (en) Methods for treating ocular conditions
JOP20190164B1 (ar) تركيبات وطرق لعلاج داء فاربر
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
WO2017161344A8 (en) Compositions and methods for treating parasitic diseases
IL273436A (en) Methods and preparations for treating itching, dry skin and related diseases using CCR3 inhibitors
PH12020551206A1 (en) Farber disease markers and uses thereof
MX2019014475A (es) Formulaciones de lixivaptan para el tratamiento de enfermedades poliquisticas.